These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 23026611)

  • 1. Impact of model for end-stage liver disease score on long-term survival following liver transplantation for hepatocellular carcinoma.
    Roma J; Balbi E; Pacheco-Moreira L; Zyngier I; Araujo A; Agoglia L; Steinbruck K; Velaverde LG; Martinho JM
    Transplant Proc; 2012 Oct; 44(8):2423-7. PubMed ID: 23026611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Living donor liver transplantation for hepatocellular carcinoma.
    Isik B; Ince V; Karabulut K; Kayaalp C; Yilmaz S
    Transplant Proc; 2012; 44(6):1713-6. PubMed ID: 22841251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of locoregional therapy before living donor liver transplantation in patients with hepatocellular carcinoma who meet the Milan criteria.
    Kim JM; Kwon CH; Joh JW; Choi MS; Lee JH; Koh KC; Paik SW; Kim GS; Kim SJ; Lee SK; Yoo BC
    Transplant Proc; 2012 Mar; 44(2):403-8. PubMed ID: 22410028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Living donor liver transplantation for hepatocellular carcinoma: the impact of neo-adjuvant treatments on the long term results.
    Di Sandro S; Giacomoni A; Slim A; Lauterio A; Mangoni I; Mihaylov P; Pirotta V; Aseni P; De Carlis L
    Hepatogastroenterology; 2012; 59(114):505-10. PubMed ID: 22353516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Younger age and presence of macrovascular invasion were independent significant factors associated with poor disease-free survival in hepatocellular carcinoma patients undergoing living donor liver transplantation.
    Wai CT; Woon WA; Tan YM; Lee KH; Tan KC
    Transplant Proc; 2012 Mar; 44(2):516-9. PubMed ID: 22410059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience.
    Schwartz JJ; Pappas L; Thiesset HF; Vargas G; Sorensen JB; Kim RD; Hutson WR; Boucher K; Box T
    Liver Transpl; 2012 Apr; 18(4):423-33. PubMed ID: 22250078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Living-donor liver transplantation associated with higher incidence of hepatocellular carcinoma recurrence than deceased-donor liver transplantation.
    Park MS; Lee KW; Suh SW; You T; Choi Y; Kim H; Hong G; Yi NJ; Kwon CH; Joh JW; Lee SK; Suh KS
    Transplantation; 2014 Jan; 97(1):71-7. PubMed ID: 24056623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary versus salvage living donor liver transplantation for patients with hepatocellular carcinoma: impact of microvascular invasion on survival.
    Moon JI; Kwon CH; Joh JW; Choi GS; Jung GO; Kim JM; Shin M; Choi SJ; Kim SJ; Lee SK
    Transplant Proc; 2012 Mar; 44(2):487-93. PubMed ID: 22410053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved outcome of adult recipients with a high model for end-stage liver disease score and a small-for-size graft.
    Yi NJ; Suh KS; Lee HW; Shin WY; Kim J; Kim W; Kim YJ; Yoon JH; Lee HS; Lee KU
    Liver Transpl; 2009 May; 15(5):496-503. PubMed ID: 19399732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver transplantation for hepatocellular carcinoma using extended criteria donor grafts.
    Sotiropoulos GC; Tagkalos E; Fouzas I; Vernadakis S; Mathé Z; Treckmann J; Paul A
    Transplant Proc; 2012 Nov; 44(9):2730-3. PubMed ID: 23146507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wait and transplant for stage 2 hepatocellular carcinoma with deceased-donor liver grafts.
    Chan SC; Sharr WW; Chok KS; Chan AC; Lo CM
    Transplantation; 2013 Dec; 96(11):995-9. PubMed ID: 23924774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Late recurrence of hepatocellular carcinoma after liver transplantation: is an active surveillance for recurrence needed?
    Castroagudín JF; Molina-Pérez E; Ferreiro-Iglesias R; Abdulkader I; Otero-Antón E; Tomé S; Varo-Pérez E
    Transplant Proc; 2012; 44(6):1565-7. PubMed ID: 22841215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma.
    Samuel D; Colombo M; El-Serag H; Sobesky R; Heaton N
    Liver Transpl; 2011 Oct; 17 Suppl 2():S6-13. PubMed ID: 21858912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma.
    An HJ; Jang JW; Bae SH; Choi JY; Yoon SK; Lee MA; You YK; Kim DG; Jung ES
    Liver Transpl; 2012 Dec; 18(12):1406-14. PubMed ID: 22821639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver transplantation for hepatocellular carcinoma: defining the impact of using extended criteria liver allografts.
    Facciuto ME; Singh MK; Katta U; Samaniego S; Sharma J; Rodriguez-Davalos M; Sheiner P; Kim-Schluger L; Wolf DC
    Transplantation; 2011 Aug; 92(4):446-52. PubMed ID: 21694662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment strategy for recurrent hepatocellular carcinoma: salvage transplantation, repeated resection, or radiofrequency ablation?
    Chan AC; Chan SC; Chok KS; Cheung TT; Chiu DW; Poon RT; Fan ST; Lo CM
    Liver Transpl; 2013 Apr; 19(4):411-9. PubMed ID: 23447460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgical treatment of hepatocellular carcinoma beyond Milan criteria. Results of liver resection, salvage transplantation, and primary liver transplantation.
    Facciuto ME; Koneru B; Rocca JP; Wolf DC; Kim-Schluger L; Visintainer P; Klein KM; Chun H; Marvin M; Rozenblit G; Rodriguez-Davalos M; Sheiner PA
    Ann Surg Oncol; 2008 May; 15(5):1383-91. PubMed ID: 18320284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: comparable survival and recurrence.
    Sandhu L; Sandroussi C; Guba M; Selzner M; Ghanekar A; Cattral MS; McGilvray ID; Levy G; Greig PD; Renner EL; Grant DR
    Liver Transpl; 2012 Mar; 18(3):315-22. PubMed ID: 22140013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of hepatocellular carcinoma treated by liver transplantation: comparison of living donor and deceased donor transplantation.
    Li C; Wen TF; Yan LN; Li B; Yang JY; Wang WT; Xu MQ; Wei YG
    Hepatobiliary Pancreat Dis Int; 2010 Aug; 9(4):366-9. PubMed ID: 20688599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting survival after liver transplantation using up-to-seven criteria in patients with hepatocellular carcinoma.
    de Ataide EC; Garcia M; Mattosinho TJ; Almeida JR; Escanhoela CA; Boin IF
    Transplant Proc; 2012 Oct; 44(8):2438-40. PubMed ID: 23026614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.